Secondary Prevention clinical trials at UC Health
1 research study open to new patients
open to eligible people ages up to 18 years
This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.
at UC Davis